poisar

Stocks · News reference

Redhill Biopharma Stock Doubles In One Session — Here's Why

Vandana Singh

RedHill Biopharma divests Talicia to Apotex, boosting liquidity and funding its commercial growth strategy and RHB-102 development.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

RDHL
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Benzinga Newsdesk

    RedHill Biopharma’s Partner University Of Oklahoma Receives $2.9M In Funding From National Cancer Institute To Study, In Clinical Trials, Whether RedHill's Opaganib, Given After CAR T-Cell Therapy, May Help Immune Cells Fight Cancer More Effectively

    RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that its partner, the University of Oklahoma (OU), has received $2.9 million in

    RDHL
  4. Delveinsight

    Nontuberculous Mycobacterial Infections Market to Showcase Growth at a CAGR of 12.6% During the Forecast Period (2026–2036), Driven by Rising Disease Burden and Emerging Therapies | DelveInsight

    The nontuberculous mycobacterial (NTM) infections market is projected to grow at a CAGR of 12.6% from 2026-2036, valued at USD 750 million in 2025. Growth is driven by rising disease prevalence, improved diagnostics, and emerging therapies including Omadacycline (NUZYRA), MRX-5, Epetraborole, and RHB-204. The US represents the largest market with approximately 400,000 diagnosed NTM cases across the 7MM countries.

    ANTXRDHLINSM